Compare DOLE & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOLE | MPLT |
|---|---|---|
| Founded | 1851 | 2018 |
| Country | Ireland | United States |
| Employees | N/A | 133 |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2021 | N/A |
| Metric | DOLE | MPLT |
|---|---|---|
| Price | $14.05 | $36.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $15.00 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 1.1M | 437.1K |
| Earning Date | 05-11-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $9,172,907,000.00 | N/A |
| Revenue This Year | $4.93 | N/A |
| Revenue Next Year | $1.72 | N/A |
| P/E Ratio | $42.48 | ★ N/A |
| Revenue Growth | ★ 8.23 | N/A |
| 52 Week Low | $12.52 | $12.24 |
| 52 Week High | $16.51 | $37.61 |
| Indicator | DOLE | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 69.30 |
| Support Level | $13.80 | $26.20 |
| Resistance Level | $14.51 | N/A |
| Average True Range (ATR) | 0.32 | 2.49 |
| MACD | -0.00 | 0.82 |
| Stochastic Oscillator | 53.49 | 92.55 |
Dole PLC operates in the North American and European markets for fresh fruits and vegetables. The company's segment includes Fresh Fruit; Diversified Fresh Produce - EMEA; Diversified Fresh Produce - Americas and ROW. It generates maximum revenue from the Diversified Fresh Produce - EMEA segment. Diversified Fresh Produce - EMEA segment includes Dole's Irish, Dutch, Spanish, Portuguese, French, Italian, U.K., Swedish, Danish, South African, Eastern European, and Brazilian businesses, the majority of which sell a variety of imported and local fresh fruits and vegetables through retail, wholesale and, in some instances, food service channels across the European marketplace. Geographically, the company operates in United States, Ireland, U.K. Spain, Sweden, and Others.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.